Propofol

Propofol is a potent intravenous general anesthetic used for the induction and maintenance of anesthesia and sedation. As a GABA-A receptor agonist, it provides rapid onset and quick recovery for surgical and intensive care patients.

Propofol dosing is highly individualized based on the patient's weight, age, physical status (ASA classification), and the specific requirements of the procedure.

Induction of General Anesthesia

For healthy adults under 55 years of age (ASA I or II), the typical induction dose is 2.0 to 2.5 mg/kg of body weight. This is usually administered as a slow IV bolus (approximately 40 mg every 10 seconds) until the onset of anesthesia. Patients over 55 or those with significant comorbidities (ASA III or IV) typically require much lower doses, often ranging from 1.0 to 1.5 mg/kg, administered more slowly to minimize cardiovascular depression.

Maintenance of General Anesthesia

Maintenance is usually achieved via continuous infusion. For healthy adults, the rate typically ranges from 100 to 200 mcg/kg/min (6 to 12 mg/kg/hr). If used as part of a balanced anesthesia technique with opioids or nitrous oxide, these rates may be reduced by 25-50%.

ICU Sedation

In the intensive care unit, propofol is started at a low rate of 5 mcg/kg/min and titrated upward in increments of 5 to 10 mcg/kg/min every 5 to 10 minutes until the desired level of sedation is achieved. Maintenance rates for ICU sedation typically fall between 5 and 50 mcg/kg/min. Long-term use at rates exceeding 50 mcg/kg/min is generally discouraged due to the risk of Propofol Infusion Syndrome (PRIS).

Propofol is approved for the induction of anesthesia in children aged 3 years and older. The required dose per kilogram is generally higher than in adults because children have a larger volume of distribution and higher clearance rates.

• Induction (ages 3-16): 2.5 to 3.5 mg/kg administered over 20-30 seconds.
• Maintenance: 125 to 300 mcg/kg/min.

Note: Propofol is NOT approved for ICU sedation in pediatric patients or for induction in infants under 3 years old in most jurisdictions, as safety and efficacy have not been established for these uses.

Renal Impairment

No specific dosage adjustment is required for patients with renal failure or those undergoing hemodialysis, as the pharmacokinetics of propofol are not significantly altered by kidney function. However, the lipid emulsion itself should be monitored in patients with pre-existing renal issues that might affect lipid clearance.

Hepatic Impairment

While the liver is the primary site of metabolism, clinical studies have shown that propofol's pharmacokinetics are not significantly changed in patients with cirrhosis. However, because these patients may be more sensitive to the sedative and cardiovascular effects, healthcare providers often titrate the dose more conservatively.

Elderly Patients

Patients over the age of 65 require a significant dose reduction (often 20-50% less than younger adults). This population has a smaller volume of distribution and decreased plasma clearance, making them more susceptible to profound hypotension and apnea.

Propofol is administered exclusively by intravenous injection or infusion. Because the injection can be painful (a common side effect), it is often preceded by a small dose of lidocaine or administered into a large vein (such as the antecubital fossa).

• Storage: Store at controlled room temperature (20°C to 25°C). Do not freeze.
• Preparation: Shake well before use. The emulsion must be used immediately after opening (within 6 hours for a syringe or 12 hours for an infusion bottle) to prevent bacterial contamination.

As propofol is administered only in a clinical setting by healthcare professionals, a missed dose is not applicable in the traditional sense. If an infusion is interrupted, the patient will likely regain consciousness very quickly, and the healthcare provider will restart the infusion as necessary.

An overdose of propofol typically manifests as profound cardiovascular and respiratory depression.

• Signs: Severe hypotension (low blood pressure), bradycardia (slow heart rate), and apnea (cessation of breathing).
• Emergency Measures: Treatment involves immediate cessation of the propofol infusion, manual ventilation with 100% oxygen, and the administration of intravenous fluids and vasopressors (such as ephedrine or phenylephrine) to support blood pressure. Atropine may be used to treat severe bradycardia.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Propofol is generally well-tolerated when administered by experts, but certain side effects are extremely common:

• Injection Site Pain: Occurring in up to 70% of patients, this is described as a sharp, stinging, or burning sensation in the vein during the initial injection. This is caused by the activation of the kinin-kallikrein system by the aqueous phase of the emulsion. Healthcare providers often mitigate this by using a larger vein or pre-treating with lidocaine.
• Hypotension: A drop in blood pressure is expected during induction. Propofol causes systemic vasodilation and decreases myocardial contractility. This effect is more pronounced in elderly or dehydrated patients.
• Apnea: Most patients will stop breathing for 30 to 90 seconds following an induction dose. This is a normal pharmacological effect, and the anesthesia provider is prepared to assist with ventilation.
• Involuntary Muscle Movements

Propofol is a high-alert medication that should only be used in a controlled clinical environment. The most critical safety concern is the risk of profound respiratory depression and cardiovascular collapse. Because propofol has a very narrow therapeutic index, the difference between a 'sedative' dose and a dose that causes complete cessation of breathing is small. Patients must be continuously monitored with pulse oximetry, electrocardiogram (ECG), and blood pressure measurements throughout the duration of its use.

No FDA black box warnings for Propofol. However, the FDA mandates a 'boxed' style warning in the labeling regarding the Administration Requirements: The drug should only be given by those trained in anesthesia, and the patient must be monitored at all times by a professional not performing the procedure. This is to ensure that if the patient stops breathing, someone is immediately available to manage the airway.

There are few absolute contraindications for drug combinations with propofol, as it is often used in 'polypharmacy' anesthesia. However, it should never be mixed in the same IV line with drugs that cause the emulsion to break (de-emulsification), such as certain highly acidic solutions.

• Opioids (e.g., Fentanyl, Morphine, Hydromorphone): Combining propofol with opioids is standard practice but results in profound synergy. This significantly increases the risk of respiratory depression and hypotension. The dose of propofol must be reduced when opioids are used concurrently.
• Benzodiazepines (e.g., Midazolam, Diazepam): These drugs also act on the GABA receptor. When used with propofol, they can cause prolonged sedation and a much higher risk of airway obstruction. This combination was a primary factor in several high-profile medical fatalities involving propofol.

Conditions where Propofol must NEVER be used:

• Known Hypersensitivity: Patients with a documented anaphylactic allergy to propofol or any of its components (soybean oil, egg lecithin, glycerol, or EDTA/sodium metabisulfite depending on the brand).
• Egg and Soy Anaphylaxis: Because the lipid emulsion is derived from these sources, a history of life-threatening allergic reaction to these foods is an absolute contraindication.
• Lack of Resuscitation Equipment: It is contraindicated to use propofol in any setting that does not have immediate access to oxygen, suction, advanced airway equipment (intubation supplies), and emergency cardiovascular drugs.

Conditions requiring careful risk-benefit analysis:

Propofol is classified as FDA Pregnancy Category B (or considered 'generally safe for short-term use' under newer labeling). It does cross the placenta and can cause CNS depression in the fetus. It is not recommended for use in obstetrics, including Cesarean sections, because the high doses required for induction can lead to neonatal depression (floppy baby syndrome). However, it may be used for non-obstetric surgery during pregnancy if the benefits outweigh the risks. There is no clear evidence of teratogenicity (birth defects) in humans at standard clinical doses.

Propofol is excreted into human breast milk in small amounts. However, research indicates that the amount ingested by an infant through breastfeeding is negligible and unlikely to cause any clinical effects. Current guidelines from the Association of Anaesthetists suggest that breastfeeding can be safely resumed as soon as the mother is awake and alert enough to hold the baby.

Propofol is approved for induction and maintenance of anesthesia in children 3 years and older. It is NOT approved for ICU sedation in the pediatric population. This restriction followed reports of increased mortality and Propofol Infusion Syndrome (PRIS) in children receiving long-term infusions in intensive care. Children often require higher mg/kg doses than adults to achieve the same level of anesthesia due to their higher metabolic rate.

Propofol acts as a positive allosteric modulator of the GABA-A receptor. It binds to the beta-subunits of the transmembrane receptor complex, which increases the conductance of chloride ions. This action mimics and enhances the effect of the endogenous inhibitory neurotransmitter GABA. By hyperpolarizing the neurons in the reticular activating system and the cerebral cortex, propofol effectively 'shuts down' the signaling required for consciousness. At higher concentrations, it can also act as a direct agonist of the GABA-A receptor and may inhibit the NMDA (glutamate) receptor, further suppressing excitatory neurotransmission.

The onset of action is extremely rapid, occurring within 30 to 40 seconds of IV administration. The duration of a single bolus dose is short (5 to 10 minutes) due to rapid redistribution from the brain to the muscles and fat. Propofol also causes a dose-dependent decrease in systemic vascular resistance and myocardial contractility, leading to a drop in blood pressure. It is a potent respiratory depressant, causing a decrease in tidal volume and respiratory rate.

| Parameter | Value |